心可舒胶囊联合氯吡格雷对冠心病心绞痛患者血管内皮功能、血液流变学及炎症因子的影响

摘要 目的：观察心可舒胶囊联合氯吡格雷对冠心病心绞痛患者血管内皮功能、血液流变学及炎症因子的影响。方法：选取2020年3月~2021年10月期间中国人民解放军东部战区总医院收治的92例冠心病心绞痛患者。按照信封抽签法分为对照组（46例）和观察组（46例）。对照组患者接受氯吡格雷治疗，观察组接受心可舒胶囊联合氯吡格雷治疗，对比两组疗效、血管内皮功能、血液流变学、炎症因子、心绞痛发作频率、硝酸甘油用量、心绞痛发作持续时间及不良反应。结果：与对照组相比，观察组治疗1个月后的临床总有效率更高（P<0.05）。与对照组相比，观察组治疗1个月后全血黏度、血浆比黏度、红细胞聚集指数更低（P<0.05）。与对照组相比，观察组治疗1个月后内皮素-1（ET-1）更低，一氧化氮（NO）更高（P<0.05）。与对照组相比，观察组治疗1个月后白介素-6（IL-6）、超敏C反应蛋白（hs-CRP）、单核细胞趋化蛋白-1（MCP-1）更低（P<0.05）。与对照组相比，观察组治疗1个月后心绞痛发作频率、硝酸甘油用量更少，心绞痛发作持续时间更短（P<0.05）。两组不良反应发生率组间对比无统计学差异（P>0.05）。结论：心可舒胶囊联合氯吡格雷可改善冠心病心绞痛患者临床症状，改善血管内皮功能和血液流变学，降低炎症因子水平，效果显著。

Effects of Xinkeshu Capsule Combined with Clopidogrel on Vascular Endothelial Function, Hemorheology and Inflammatory Factors in Patients with Coronary Heart Disease and Angina Pectoris

ABSTRACT Objective: To observe the effects of Xinkeshu capsule combined with clopidogrel on vascular endothelial function, hemorheology and inflammatory factors in patients with coronary heart disease and angina pectoris. Methods: 92 patients with coronary heart disease and angina pectoris who were treated in General Hospital of Eastern Theater of the Chinese People''s Liberation Army from March 2020 to October 2021 were selected. According to the envelope lottery method, they were divided into control group (46 cases) and observation group (46 cases). The patients in the control group received clopidogrel treatment, and the observation group received Xinkeshu capsule combined with clopidogrel treatment. The efficacy, vascular endothelial function, hemorheology, inflammatory factors, frequency of angina pectoris attack, dosage of nitroglycerin, duration of angina pectoris attack and adverse reactions were compared between the two groups. Results: Compared with the control group, the total clinical effective rate of the observation group at 1 month after treatment was higher (P<0.05). Compared with the control group, the whole blood viscosity, plasma specific viscosity and erythrocyte aggregation index of the observation group at 1 month after treatment were lower (P<0.05). Compared with the control group, endothelin-1 (ET-1) was lower, and nitric oxide (NO) of the observation group at 1 month after treatment was higher (P<0.05). Compared with the control group, the levels of interleukin-6 (IL-6), high-sensitivity C-reactive protein (hs-CRP) and monocyte chemoattractant protein-1 (MCP-1) of the observation group at 1 month after treatment were lower (P<0.05). Compared with the control group, the frequency of angina pectoris attack, the dosage of nitroglycerin and the duration of angina pectoris attack of the observation group at 1 month after treatment were less (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusion: Xinkeshu capsule combined with clopidogrel can improve the clinical symptoms, improve vascular endothelial function and hemorheology, and reduce the level of inflammatory factors in patients with coronary heart disease and angina pectoris, and with remarkable effect.